Trials / Unknown
UnknownNCT04895930
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
A Multi-center, One-arm Clinical Trial of Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Shanghai Chest Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib combined with Anlotinib as the first-line treatment in locally advanced or metastatic non-small cell lung cancer with sensitive EGFR mutations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Furmonertinib | 80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg). |
| DRUG | Anlotinib | 10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg). |
Timeline
- Start date
- 2021-10-12
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
- First posted
- 2021-05-20
- Last updated
- 2023-01-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04895930. Inclusion in this directory is not an endorsement.